Latest news with #ZentekLtd
Associated Press
3 days ago
- Business
- Associated Press
Zentek Announces Test Results Validating ZenGUARD(TM) Enhanced Air Filters as a High-Performance Solution for ASHRAE Standard 241 Compliance
GUELPH, ON / ACCESS Newswire / June 12, 2025 / Zentek Ltd. ('Zentek' or the 'Company') (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company, is pleased to announce new independent test results comparing the viral filtration efficiency ('VFE') of ZenGUARD™ Enhanced Air Filters against the bacteriophage MS2 compared to equivalent Minimum Efficiency Reporting Value ('MERV')-rated filters without ZenGUARD™. The testing was performed by the third-party ISO 17025:2017 certified lab LMS Technologies Inc. ('LMS'), which specializes in the testing and certification of filter manufacturers across the world in line with American Society of Heating, Refrigerating and Air-Conditioning Engineers ('ASHRAE') standards. Test Results ZenGUARD™ Enhanced Air Filters achieved an average infectious aerosol removal efficiency (εPR) of MS2 bacteriophage of 42% compared to an untreated filter, which achieved an average εPR of 16%. These strong results align with previous tests performed with bacteriophage Phi6, which is often used as a surrogate for SARS-CoV-2 and other enveloped viruses. This milestone adds to a growing body of third-party validation demonstrating ZenGUARD™ Enhanced Air Filter's unique combination of effectiveness and simplicity. To highlight this, the Company believes ZenGUARD™ Enhanced Air Filters are the only technology that can accomplish the following simultaneously: Highly effective at controlling infectious aerosol in line with ASHRAE 241 Achieve this without an increase in pressure drop, energy consumption and carbon emissions Work with existing heating, ventilation, and air conditioning units Not require any additional equipment Extend filter life and reduce changeout frequency compared to more dense filters reducing labour and waste disposal costs ASHRAE Standard 241-2023: Control of Infectious Aerosols ASHRAE Standard 241 is new guidance designed to help buildings reduce the spread of airborne viruses, like SARS-CoV-2, influenza, and other respiratory illnesses. It sets clear guidelines for Equivalent Clean Airflow ('ECA') (from ventilation, filtration, or air cleaning) that is needed to lower the risk of infection in indoor spaces. This is important because it gives schools, offices, and other public buildings a science-based way to improve indoor air quality and the health of building occupants. ASHRAE 241 focuses specifically on health and infection control, making it a key tool for creating safer indoor environments. The standard includes the use of MS2 bacteriophage as a standardized surrogate for evaluating the control of infectious aerosol. Its inclusion ensures a consistent benchmark for assessing the effectiveness of technologies such as ZenGUARD™ Enhanced Air Filters. Based on these new test results using MS2 bacteriophage, the Company now has science-based, directly comparable data demonstrating that ZenGUARD™ is highly effective at controlling infectious aerosols and is fully aligned with ASHRAE Standard 241 testing methodology. ZenGUARD™'s higher εPR translates to a higher ECA, making it a practical and effective option for inclusion in building readiness plans prepared by facility managers and building operators. Importantly, ASHRAE 241 assigns an εPR of zero to any filter rated below MERV 11A. However, ZenGUARD™, which has been independently tested with MS2, can be assigned an EPR of 42%, even when applied to a lower-rated MERV 9A filter. This allows facility managers to confidently adopt ZenGUARD™ technology without needing to upgrade to MERV 11A or higher filters, which may be incompatible with existing HVAC systems. 'These exciting new test results not only reinforce ZenGUARD™'s proven ability to improve indoor quality without increasing energy consumption - they highlight how our solution meets the requirements of ASHRAE 241, the most recent and relevant third-party guidance for controlling infectious aerosols in buildings,' said Greg Fenton, CEO of Zentek Ltd. 'Conventional panel filters - like electrostatically charged MERV 13s - are designed to trap dust and often fall short over time when it comes to impacting aerosols responsible for respiratory infections. In contrast, our filters were specifically designed to enhance mechanical filtration of infectious aerosol via the unique properties of our patented ZenGUARD™ technology - and we have now demonstrated our ability to do this in line with the only standard focused solely on infection control. As building operators face growing pressure to meet new air quality standards and carbon reduction targets, we're proud to offer our unique technology that is proven to effectively keep indoor spaces safe, while also reducing total cost of ownership and carbon emissions.' About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters Zentek's ZenGUARD™ production facility is in Guelph, Ontario. Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets. For further information: [email protected] Ryan Shacklock Email: [email protected] 306-270-9610 To find out more about Zentek, please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at . Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Zentek Ltd. press release
Yahoo
09-04-2025
- Business
- Yahoo
Zentek Announces Closing of $2,000,000 Non-Brokered Private Placement of Debenture Units
Guelph, Ontario--(Newsfile Corp. - April 9, 2025) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company"), announces that it has closed a non-brokered private placement (the "Offering") of debenture units (the "Debenture Units") through the issuance of 2,000 Debenture Units for gross proceeds of $2,000,000. Each Debenture Unit consists of: (i) $1,000 principal amount of 5% secured convertible debentures of the Company (each, a "Convertible Debenture"); and (ii) 454 warrants (the "Warrants") to purchase common shares in the capital of the Company (the "Common Shares"). Each Convertible Debenture will mature on April 9, 2028, (the "Maturity Date") and bears interest at a rate of 5% per annum payable as a balloon payment on the Maturity Date. Each Convertible Debenture is convertible at the option of the holder, in whole or in part, into Common Shares, at any time prior to the Maturity Date at a conversion price of $2.20 per Common Share (the "Conversion Price"). The Company has the option to force the conversion of the Convertible Debentures into Common Shares at the Conversion Price at any time after the second anniversary of closing and prior to the Maturity Date in the event that the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the "TSXV") for the preceding 30 business days exceeds $4.40. The Convertible Debentures are secured by the Company's interest in the 521 mining claims held by the Company's subsidiary Albany Graphite Corp., located north of Lake Superior and southwest of James Bay in Northern Ontario (the "Secured Assets"), with a first ranking above all other creditors or loans by the Company. 908,000 Warrants were issued pursuant to the Offering, each entitling the holder to purchase one Common Share at the Conversion Price until the Maturity Date. The Warrants will only vest and be exercisable: (i) in the event, and from the date, that the Company completes a sale or otherwise transfers all of its right title and interests in the Secured Assets to a third party; and (ii) in such number equal to the result of dividing the outstanding principal amount of Convertible Debentures held by the holder at the time of exercise by the Conversion Price. Net proceeds from the Offering will be used for working capital and general corporate purposes. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of TSXV. All securities issued in connection with the Offering are subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario. For further information: Investorrelations@ Ryan ShacklockSenior VP, Strategy & Business DevelopmentEmail: rshacklock@ 306-270-9610 To find out more about Zentek, please visit our website at A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
12-03-2025
- Business
- Associated Press
Zentek Completes Shelf-Life Efficacy Testing for ZenGUARD(TM) Enhanced Air Filter Commercialization
GUELPH, ON / ACCESS Newswire / March 12, 2025 / Zentek Ltd. ('Zentek' or the 'Company') (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company announces that shelf-life efficacy testing has been completed on aged ZenGUARD™ Enhanced Air Filters, which is required for medical device compliance. Highlights ZenGUARD™ Enhanced Air Filters were aged for 20 months prior to testing to establish the product's shelf life Viral filtration efficiency ('VFE') was unchanged after aging demonstrating that the ZenGUARD™ coating has a consistent performance over a duration of 20 months ZenGUARD™ Enhanced Air Filters On November 27, 2024, Zentek announced that the Company will manufacture and sell its ZenGUARD™ Enhanced Air Filters as a Class I medical device under its medical device establishment licence ('MDEL'). The change in regulatory pathway required the completion of 'End Product Stability and Performance Testing.' These tests are essential for medical devices as products must demonstrate consistent performance and safety of the device until a subsequent expiry date. The expiry date must be clearly identified on the label of all medical devices. ZenGUARD™ Enhanced Air Filters were real-time aged for 20 months and then submitted to LMS Technologies, Inc. ('LMS') for VFE and shedding testing. The VFE was tested for the aged filters to determine the reduction in bioaerosols that is achieved under normal operating conditions with an airflow of 500 ft/min and was consistent with ASHRAE 241 Section L standards. The recently completed testing of the 20-month aged filters measured an initial VFE of 38.1% which was similar to the original test performance of 37.7%. Likewise, a shedding test on the 20-month-aged filters was completed using a laser particle counter to determine the number and size of particles in the airstream under normal operating conditions (500 ft/min airflow). The shedding test demonstrated that the coating maintains excellent adhesion to the substrate over 20 months as the number of particles counted in the airstream after passing through the filter were within statistical deviation with the background particle counts measured with no filter present in the test chamber. Based on the VFE and shedding test results, ZenGUARD™ Enhanced Air Filters will be labelled with a 20-month expiry from the date of manufacture. The Company continues to prioritize the completion of all required documentation to support the manufacture and sale of ZenGUARD™ Enhanced Air Filters under its existing MDEL alongside ZenGUARD™ Surgical Masks. This documentation will be completed in compliance with Canadian Medical Device Regulations and ISO 13485:2016 Quality Management System for medical devices. Greg Fenton, Zentek's CEO, commented: 'The pathway to commercialization for ZenGUARD™ Enhanced Air Filters has been a long journey and we are pleased to have finally completed all testing necessary required for a medical device. These recent results further demonstrate to users that ZenGUARD™ Enhanced Air Filters are an effective and safe solution to help reduce the transmission of infectious bioaerosols up to the expiry date. We look forward to providing further announcements as we move towards commercialization.' About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters. Zentek's ZenGUARD™ production facility is in Guelph, Ontario. Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets. Ryan Shacklock 306-270-9610 To find out more about Zentek, please visit our website at A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yahoo
04-03-2025
- Business
- Yahoo
Zentek Announces US$30 Million At-The-Market Offering in the United States
Guelph, Ontario--(Newsfile Corp. - March 3, 2025) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company"), an intellectual property technology development and commercialization company is pleased to announce it has entered into an at-the-market offering agreement (the "ATM Agreement"), dated as of today pursuant to which the Company proposes to issue and sell such number of common shares in the capital of the Company (the "Common Shares") as would result in aggregate gross proceeds to the Company of up to US$30 million (the "Offering"). Rodman & Renshaw LLC is acting as the exclusive sales agent for the Offering. Sales of Common Shares will be made through an "at-the-market offering" as defined in Rule 415(a)(4) promulgated under the U.S. Securities Act of 1933, as amended, made directly on the Nasdaq Capital Markets ("Nasdaq"), or any other recognized marketplace on which the Common Shares are listed, quoted or traded in the United States or through a market maker. No offers or sales of Common Shares will be made in Canada on the TSX Venture Exchange or other trading markets in Canada. The Offering will remain in effect until the aggregate gross sales proceeds of Common Shares sold pursuant to the ATM Agreement equals US$30 million, unless terminated prior to such date by any of the parties in accordance with the ATM Agreement. Sales of Common Shares, if any, will be made at or related to then prevailing market prices and, as a result, prices may vary. Net proceeds from the Offering, if any, will be used for corporate purposes as described in the Prospectus Supplement referenced below. The Common Shares will be issued pursuant to a prospectus supplement dated March 3, 2025 (the "Prospectus Supplement") to the base prospectus included in the Company's existing U.S. registration statement (the "Registration Statement") on Form F-3 (File No. 333-278886) dated April 23, 2024, as amended on April 24, 2024, and April 30, 2024, and declared effective by the United States Securities and Exchange Commission (the "SEC") on May 3, 2024. The Offering is being made only by means of the Prospectus Supplement forming part of the effective Registration Statement. The Prospectus Supplement relating to the Offering has been filed with the SEC. Electronic copies of the Prospectus Supplement may be obtained on the SEC's website at and may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at info@ This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™ is shown to have enhanced viral filtration efficiency for surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets. For further information: investorrelations@ Ryan ShacklockTel: (306) 270-9610Email: rshacklock@ To find out more about Zentek, please visit our website at A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at or on the SEC's website at as applicable. Forward-Looking Statements This news release contains forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the anticipated use of proceeds from the Offering. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
